Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Change in Cash (2017 - 2021)

Cogent Biosciences (COGT) has 4 years of Change in Cash data on record, last reported at $16.8 million in Q4 2021.

  • For Q4 2021, Change in Cash fell 85.11% year-over-year to $16.8 million; the TTM value through Dec 2021 reached -$22.5 million, down 110.99%, while the annual FY2025 figure was $214.3 million, 376.82% up from the prior year.
  • Change in Cash reached $16.8 million in Q4 2021 per COGT's latest filing, up from -$15.2 million in the prior quarter.
  • Across five years, Change in Cash topped out at $112.8 million in Q4 2020 and bottomed at -$15.2 million in Q3 2021.
  • Average Change in Cash over 4 years is $12.0 million, with a median of -$2.9 million recorded in 2018.
  • Peak YoY movement for Change in Cash: crashed 497.02% in 2019, then soared 1433.29% in 2020.
  • A 4-year view of Change in Cash shows it stood at $6.4 million in 2018, then crashed by 232.67% to -$8.5 million in 2019, then skyrocketed by 1433.29% to $112.8 million in 2020, then crashed by 85.11% to $16.8 million in 2021.
  • Per Business Quant database, its latest 3 readings for Change in Cash were $16.8 million in Q4 2021, -$15.2 million in Q3 2021, and -$12.6 million in Q2 2021.